Lixte Biotechnology Holdings Stock Market Value
| LIXT Stock | USD 2.97 0.07 2.41% |
| Symbol | Lixte |
Is there potential for Biotechnology market expansion? Will Lixte introduce new products? Factors like these will boost the valuation of Lixte Biotechnology. Expected growth trajectory for Lixte significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lixte Biotechnology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lixte Biotechnology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lixte Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Lixte Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lixte Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lixte Biotechnology.
| 11/26/2025 |
| 02/24/2026 |
If you would invest 0.00 in Lixte Biotechnology on November 26, 2025 and sell it all today you would earn a total of 0.00 from holding Lixte Biotechnology Holdings or generate 0.0% return on investment in Lixte Biotechnology over 90 days. Lixte Biotechnology is related to or competes with Kairos Pharma, Lexaria Bioscience, Allarity Therapeutics, Cingulate, Briacell Therapeutics, Pulmatrix, and Hoth Therapeutics. Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzym... More
Lixte Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lixte Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lixte Biotechnology Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 20.41 | |||
| Value At Risk | (6.85) | |||
| Potential Upside | 8.48 |
Lixte Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lixte Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lixte Biotechnology's standard deviation. In reality, there are many statistical measures that can use Lixte Biotechnology historical prices to predict the future Lixte Biotechnology's volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (0.85) | |||
| Treynor Ratio | 3.32 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lixte Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lixte Biotechnology February 24, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 3.33 | |||
| Mean Deviation | 3.5 | |||
| Coefficient Of Variation | (1,010) | |||
| Standard Deviation | 4.63 | |||
| Variance | 21.48 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (0.85) | |||
| Treynor Ratio | 3.32 | |||
| Maximum Drawdown | 20.41 | |||
| Value At Risk | (6.85) | |||
| Potential Upside | 8.48 | |||
| Skewness | 0.7434 | |||
| Kurtosis | 0.8583 |
Lixte Biotechnology Backtested Returns
Lixte Biotechnology has Sharpe Ratio of -0.1, which conveys that the firm had a -0.1 % return per unit of risk over the last 3 months. Lixte Biotechnology exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Lixte Biotechnology's Mean Deviation of 3.5, risk adjusted performance of (0.07), and Standard Deviation of 4.63 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.14, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Lixte Biotechnology are expected to decrease at a much lower rate. During the bear market, Lixte Biotechnology is likely to outperform the market. At this point, Lixte Biotechnology has a negative expected return of -0.47%. Please make sure to verify Lixte Biotechnology's potential upside and day median price , to decide if Lixte Biotechnology performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.29 |
Poor predictability
Lixte Biotechnology Holdings has poor predictability. Overlapping area represents the amount of predictability between Lixte Biotechnology time series from 26th of November 2025 to 10th of January 2026 and 10th of January 2026 to 24th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lixte Biotechnology price movement. The serial correlation of 0.29 indicates that nearly 29.0% of current Lixte Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.29 | |
| Spearman Rank Test | 0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 0.07 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.